Literature DB >> 19273110

Cannabinoid Receptors: A brief history and what not

Euan Scott Graham1, John Clive Ashton, Michelle Glass.   

Abstract

Our understanding of the complexity of the endocannabinoid system has evolved considerably since the cloning of the receptors in the early 1990s. Since then several endogenous ligands have been identified and their respective biosynthetic pathways unravelled. This research has revealed the involvement of the cannabinoid system in a number of important physiological processes including the regulation of neurotransmitter release, pain and analgesia, energy homeostasis, and control of immune cell function. All of these events are mediated by two similar receptors, CB1 and CB2, which were initially thought to possess mutually exclusive expression profiles. Recent advances have begun to dissolve such absolutes with the discovery of CB2 in brain tissue and identification of a range of functions for CB1 in peripheral tissues. With improved understanding of the cannabinoid system comes the illumination of various roles in disease pathologies and identification of potential therapeutic targets. This review provides an overview of the current understanding of the endocannabinoid system, and then focuses on recent discoveries that we believe are likely to shape the future directions of the field.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19273110     DOI: 10.2741/3288

Source DB:  PubMed          Journal:  Front Biosci (Landmark Ed)        ISSN: 2768-6698


  23 in total

1.  Epidermal growth factor receptor transactivation by the cannabinoid receptor (CB1) and transient receptor potential vanilloid 1 (TRPV1) induces differential responses in corneal epithelial cells.

Authors:  H Yang; Z Wang; J E Capó-Aponte; F Zhang; Z Pan; P S Reinach
Journal:  Exp Eye Res       Date:  2010-07-07       Impact factor: 3.467

2.  Highly selective CB2 receptor agonist A836339 has gastroprotective effect on experimentally induced gastric ulcers in mice.

Authors:  M Salaga; H Zatorski; M Zielińska; P Mosinska; J-P Timmermans; R Kordek; M Storr; J Fichna
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-07-14       Impact factor: 3.000

Review 3.  Marijuana-based drugs: innovative therapeutics or designer drugs of abuse?

Authors:  Kathryn A Seely; Paul L Prather; Laura P James; Jeffery H Moran
Journal:  Mol Interv       Date:  2011-02

Review 4.  Immunoactive effects of cannabinoids: considerations for the therapeutic use of cannabinoid receptor agonists and antagonists.

Authors:  William E Greineisen; Helen Turner
Journal:  Int Immunopharmacol       Date:  2010-02-25       Impact factor: 4.932

5.  Adenosine A2A receptor activation stimulates collagen production in sclerodermic dermal fibroblasts either directly and through a cross-talk with the cannabinoid system.

Authors:  Pietro Enea Lazzerini; Mariarita Natale; Elena Gianchecchi; Pier Leopoldo Capecchi; Cinzia Montilli; Stefania Zimbone; Monica Castrichini; Epifania Balistreri; Gianluca Ricci; Enrico Selvi; Estrella Garcia-Gonzalez; Mauro Galeazzi; Franco Laghi-Pasini
Journal:  J Mol Med (Berl)       Date:  2011-10-28       Impact factor: 4.599

Review 6.  Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress.

Authors:  George W Booz
Journal:  Free Radic Biol Med       Date:  2011-01-14       Impact factor: 7.376

7.  Selective Activation of Cannabinoid Receptor 2 Attenuates Myocardial Infarction via Suppressing NLRP3 Inflammasome.

Authors:  Wen Yu; Guangjun Jin; Jiancheng Zhang; Wei Wei
Journal:  Inflammation       Date:  2019-06       Impact factor: 4.092

8.  Anti-aversive effects of cannabidiol on innate fear-induced behaviors evoked by an ethological model of panic attacks based on a prey vs the wild snake Epicrates cenchria crassus confrontation paradigm.

Authors:  Andrés Uribe-Mariño; Audrey Francisco; Maria Angélica Castiblanco-Urbina; André Twardowschy; Carlos José Salgado-Rohner; José Alexandre S Crippa; Jaime Eduardo Cecílio Hallak; Antônio Waldo Zuardi; Norberto Cysne Coimbra
Journal:  Neuropsychopharmacology       Date:  2011-09-14       Impact factor: 7.853

9.  Identification of a Potent and Selective Cannabinoid CB1 Receptor Antagonist from Auxarthron reticulatum.

Authors:  Mahmoud Fahmi Elsebai; Viktor Rempel; Gregor Schnakenburg; Stefan Kehraus; Christa E Müller; Gabriele M König
Journal:  ACS Med Chem Lett       Date:  2011-09-17       Impact factor: 4.345

10.  Peripheral interactions between cannabinoid and opioid systems contribute to the antinociceptive effect of crotalphine.

Authors:  F C Machado; V O Zambelli; A C O Fernandes; A S Heimann; Y Cury; G Picolo
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.